Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 214528, held by Sagent Pharms Inc. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 214528 (Ephedrine Sulfate), held by Sagent Pharms Inc, was first approved by FDA on Mar 9, 2023, with 0 approved supplements and 0 published complete response letters.
Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 9, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate50MG/ML (50MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters